LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
Endonovo Therapeutics (OTCQB: ENDV) just released a corporate update on what has been an extremely successful year for the company to date. Investors have reaped the rewards as the stock has made several large runs and looks poised for its next dance with the bulls.
A few highlights from the update include:
- ENDV repurchased $154,303 in convertible notes preventing additional shareholder dilution.
- ENDV's technology was previously shown to reduce acute inflammation in a Carrageenan Rat Footpad Edema (CFE) protocol, which is the drug/pharmaceutical industry gold standard for the initial screening of drugs and their effects on acute inflammation.
- ENDV has filed to withdraw its S-1 from registration of all the remaining shares under the Equity Purchase Agreement with Kodiak Capital, including 215,000 "Commitment Shares" issued to Kodiak Capital pursuant to the Equity Purchase Agreement. They have also notified COR Clearing, LLC of its obligation to return to the Company a total of 1.89 million unpaid shares from the Equity Purchase Agreement with Kodiak Capital.
Bio Blast Pharma Ltd. (NASDAQ: ORPN) had a massive session Wednesday, with its stock up over 150% on positive clinical results. The company announced positive results from its HopeMD Phase 2 six-month open-label clinical study in patients with oculopharyngeal muscular dystrophy (OPMD).
BioLineRx Ltd. (NASDAQ: BLRX) has enhanced and expanded the development strategy for its BL-8040 cancer therapy platform, which is currently being investigated for multiple cancer and hematological indications. These include a Phase 2 study for treating relapsed and refractory acute myeloid leukemia patients, top-line results of which are expected by the end of this month. Results from the first part of this trial continue to demonstrate substantial mobilization of leukemic cells from the bone marrow to the peripheral blood and robust induction of cancer cell apoptosis, which, combined with the reported 38% composite remission rate, strongly suggest that BL-8040 has potent anti-leukemic activity.
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) announced positive results from the Phase 3 trial of VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival. Data will be submitted for presentation at the American Society of Clinical Oncology 2016 Annual Meeting.
Inovio Pharmaceuticals Inc. (NASDAQ: INO) entered into its second big deal this week by signing a collaborative research agreement Wednesday with the Wistar Institute.
The deal between the publicly traded biotechnology company and the nonprofit research institution covers preventive and therapeutic DNA-based immunotherapy applications and products targeting cancers and infectious diseases developed by David B. Weiner and his Wistar laboratory. Inovio will have the exclusive right to in-license new intellectual property developed in this collaboration. Financial terms of the agreement were not disclosed.
Chimerix, Inc. (NASDAQ: CMRX) Chief Commercial Officer, Linda M. Richardson, presented Wednesday at Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, FL. The presentation could have a positive effect on the stock over the next few sessions. CMRX is a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs.
Out of all of these the highest profit potential lies with ENDV being under a dollar, if its major goals are achieved the increase in valuation could be relatively enormous!
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC., which owns Microcapspeculators.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC., which owns Microcapspeculators.com, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $20,000 cash by a non-affiliate third party of ENDV.
Contact:
SOURCE: ACR Communication, LLC
